Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
Top Page
Piramal Pharma Limited
(PPLPHARMA)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹193.00
▲(0.18% Upside)
Action:Reiterated
Date:04/30/26
The score is primarily driven by mixed financial performance: strong revenue growth and improved cash generation are offset by recurring net losses and inconsistent returns. Technical indicators are moderately supportive with positive momentum, while valuation is held back by a negative P/E despite a high dividend yield.
Positive Factors
Revenue Scaling
Sustained multi-year top-line growth to ~₹88.7B signals expanding commercial traction and scale across its businesses. Higher revenue base supports fixed-cost absorption, investment in capacity and R&D, and underpins the company's ability to win larger CDMO contracts and sustain hospital-generic production.
Negative Factors
Recurring Net Losses
Recurrent bottom-line losses undermine retained earnings and capital accumulation, limiting internal funding for growth or deleveraging. Persistent losses reduce ability to build reserves against industry shocks and may force reliance on debt or equity raises, diluting capital efficiency over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling
Sustained multi-year top-line growth to ~₹88.7B signals expanding commercial traction and scale across its businesses. Higher revenue base supports fixed-cost absorption, investment in capacity and R&D, and underpins the company's ability to win larger CDMO contracts and sustain hospital-generic production.
Read all positive factors
Piramal Pharma Limited (PPLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹234.48B
Dividend Yield0.08%
Average Volume (3M)264.14K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-3.08%
EPS Growth-458.85%
CountryIN
Employees6,719
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.18
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.44
Revenue Forecast (FY)₹100.93B
Piramal Pharma Limited Business Overview & Revenue Model
Company Description
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India....
How the Company Makes Money
Piramal Pharma Limited primarily makes money through three business lines: (1) Contract Development and Manufacturing (CDMO): it earns service revenue by providing end-to-end capabilities to innovator pharmaceutical companies, including process an...
Piramal Pharma Limited Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
58
Neutral
Cash Flow
66
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.46B | 88.69B | 90.61B | 81.06B | 70.32B | 64.72B |
| Gross Profit | 45.33B | 23.83B | 54.89B | 48.48B | 40.32B | 37.91B |
| EBITDA | 14.11B | 9.22B | 16.49B | 13.67B | 8.94B | 12.60B |
| Net Income | -237.40M | -3.26B | 911.30M | 178.20M | -1.86B | 3.76B |
Balance Sheet | ||||||
| Total Assets | 161.89B | 179.65B | 156.78B | 153.12B | 145.23B | 127.97B |
| Cash, Cash Equivalents and Short-Term Investments | 7.44B | 13.55B | 5.21B | 5.02B | 6.60B | 3.79B |
| Total Debt | 48.51B | 56.75B | 48.56B | 47.10B | 56.37B | 41.28B |
| Total Liabilities | 81.16B | 98.02B | 75.52B | 74.00B | 77.49B | 61.00B |
| Stockholders Equity | 80.74B | 81.63B | 81.25B | 79.11B | 67.73B | 66.97B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 5.10B | 2.28B | 2.92B | -4.81B | -1.23B |
| Operating Cash Flow | 8.90B | 14.00B | 8.92B | 10.05B | 4.84B | 7.66B |
| Investing Cash Flow | -4.68B | -8.69B | -4.77B | -4.34B | -13.39B | -18.12B |
| Financing Cash Flow | -3.61B | 2.57B | -4.41B | -4.22B | 8.18B | 7.94B |
Piramal Pharma Limited Technical Analysis
Positive
192.65
Price Trends
155.02
Positive
159.69
Positive
176.04
Negative
Market Momentum
6.13
Positive
61.00
Neutral
30.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Positive. The current price of 192.65 is above the 20-day moving average (MA) of 171.07, above the 50-day MA of 155.02, and above the 200-day MA of 176.04, indicating a neutral trend. The MACD of 6.13 indicates Positive momentum. The RSI at 61.00 is Neutral, neither overbought nor oversold. The STOCH value of 30.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PPLPHARMA.
Piramal Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹116.70B | 54.58 | ― | 0.80% | 6.38% | -4.22% | |
61 Neutral | ₹117.29B | 59.25 | ― | 0.74% | 1.43% | 29.21% | |
60 Neutral | ₹234.48B | -487.64 | ― | 0.08% | -3.08% | -458.85% | |
58 Neutral | ₹33.11B | 20.90 | ― | ― | 8.13% | 2910.16% | |
56 Neutral | ₹701.09B | 127.98 | ― | 0.12% | 10.91% | -67.33% | |
56 Neutral | ₹187.89B | 26.49 | ― | 0.19% | 2.64% | -36.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:PPLPHARMA
Piramal Pharma Limited
175.90
-30.32
-14.70%
IN:BIOCON
Biocon Limited
431.05
98.25
29.52%
IN:CONCORDBIO
Concord Biotech Ltd.
1,124.05
-397.66
-26.13%
IN:DCAL
Dishman Carbogen Amcis Ltd.
212.90
-32.00
-13.07%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
747.90
71.99
10.65%
IN:SYNGENE
Syngene International Ltd.
470.25
-163.82
-25.84%
Piramal Pharma Limited Corporate Events
Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant
May 10, 2026
Piramal Pharma Limited reported that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville, U.S., facility from May 4 to May 8, 2026, resulting in a Form 483 with three observations classified as Voluntary Action Ind...
Piramal Pharma Posts FY26 Loss but Sees Recovery Momentum Across Key Businesses
Apr 28, 2026
Piramal Pharma reported FY26 consolidated revenue from operations of ₹8,869 crore, down 3% year-on-year, with EBITDA falling 28% and the company posting a net loss after an impairment charge on intangible assets under development. Revenue wa...
Piramal Pharma Clears FY26 Results and Strengthens Board, Governance Bench
Apr 28, 2026
Piramal Pharma’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, and will publish these in line with SEBI disclosure norms. The company also appoi...
Piramal Pharma clears FY26 results and reinforces board continuity
Apr 28, 2026
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements for the quarter and full year ended 31 March 2026, in line with SEBI listing regulations, and will publish the results in newspapers as ...
Piramal Pharma Clears FY26 Results and Confirms Continuity in Board Leadership
Apr 28, 2026
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, in line with SEBI listing requirements. The company plans to publish thes...
Piramal Pharma Clears FY26 Results, Renews Top Leadership Bench
Apr 28, 2026
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, in line with SEBI listing requirements, and plans to publish these in new...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.